In recent years, anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy has become a groundbreaking treatment for advanced B-cell non-Hodgkin lymphoma [1]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.